Other connective tissue diseases such as systemic lupus erythematosus, rheumatoid arthritis, thrombophlebitis, hypersensitivity vasculitis, livedo vasculopathy, and allergic granulomatosis are ...

Anti-inflammatory medications are a cornerstone of treatment for mixed connective tissue disease (MCTD ... The effects of immunostimulatory herbal supplements on autoimmune skin diseases. J Am Acad ...

Objectives To investigate short-term prognosis and prognostic factors for connective tissue disease-associated ... M329 (adult-onset Still’s disease), M352 (Behçet’s disease), M341 (CREST syndrome), ...

Background: Mixed connective tissue disease (MCTD) with a range of clinical manifestations ... in CD4+T cell subsets[3], and abnormal activation of CD4+T cells, as well as skin tissue infiltration and ...

In a study of 182 cases of skin vasculitis ... category if aetiologies are discovered. Secondary vasculitis includes vasculitis due to infection, drugs, malignancy and connective tissue diseases. (f).

Anti-C1q antibodies are highly prevalent among patients with IgG4-RD, particularly those with renal and skin manifestations.

Anti-inflammatory medications are a cornerstone of treatment for mixed connective tissue disease (MCTD) but your diet also is important. Eating foods that suppress inflammation may help prevent ...

1–7 In particular, an association between some of the connective-tissue diseases and Hashimoto's thyroiditis (lymphadenoid goiter) has recently seemed likely. 6,8,9 Many reports of this ...

Most children with ANCA-associated vasculitis had active kidney disease and impaired renal function at diagnosis. Those with normal or minimal kidney impairment had good chance of recovery.

Connective tissue diseases are a heterogeneous group of autoimmune disorders that affect any of the body's connective tissues. These disorders can be inherited or acquired, and can present with a ...

Type I interferon (IFN) score may effectively predict disease progression in limited cutaneous systemic sclerosis (lcSSc), with patients having a high IFN activity presenting worse clinical outcomes.